BACKGROUND AND PURPOSE: The sphingosine 1-phosphate receptor agonist fingolimod reduces infarct size in rodent models of stroke and enhances blood-brain barrier integrity. Based on these observations, we hypothesized that combination of fingolimod with tissue plasminogen activator (tPA) would reduce the risk of hemorrhagic transformation associated with delayed administration of tPA. METHODS: We evaluated the effects of fingolimod in a mouse model of thromboembolic stroke, in which both the beneficial effect of reperfusion associated with early tPA treatment and hemorrhagic transformation associated with delayed administration mimic clinical observations in humans. RESULTS: Our results demonstrate that fingolimod treatment attenuates the neurological deficit and reduces infarct volume after in situ thromboembolic occlusion of the middle cerebral artery. Combination of fingolimod and tPA improves the neurological outcome of the thrombolytic therapy and reduces the risk of hemorrhagic transformation associated with delayed administration of tPA. CONCLUSIONS: This study confirms the protective efficacy of fingolimod as a treatment against ischemic stroke in another rodent model of stroke (thromboembolic occlusion), and suggests that fingolimod could potentially be used in combination with tPA to reduce the risk of brain hemorrhage.
BACKGROUND AND PURPOSE: The sphingosine 1-phosphate receptor agonist fingolimod reduces infarct size in rodent models of stroke and enhances blood-brain barrier integrity. Based on these observations, we hypothesized that combination of fingolimod with tissue plasminogen activator (tPA) would reduce the risk of hemorrhagic transformation associated with delayed administration of tPA. METHODS: We evaluated the effects of fingolimod in a mouse model of thromboembolic stroke, in which both the beneficial effect of reperfusion associated with early tPA treatment and hemorrhagic transformation associated with delayed administration mimic clinical observations in humans. RESULTS: Our results demonstrate that fingolimod treatment attenuates the neurological deficit and reduces infarct volume after in situ thromboembolic occlusion of the middle cerebral artery. Combination of fingolimod and tPA improves the neurological outcome of the thrombolytic therapy and reduces the risk of hemorrhagic transformation associated with delayed administration of tPA. CONCLUSIONS: This study confirms the protective efficacy of fingolimod as a treatment against ischemic stroke in another rodent model of stroke (thromboembolic occlusion), and suggests that fingolimod could potentially be used in combination with tPA to reduce the risk of brain hemorrhage.
Authors: Katharina Eikermann-Haerter; Jeong Hyun Lee; Izumi Yuzawa; Christina H Liu; Zhipeng Zhou; Hwa Kyoung Shin; Yi Zheng; Tao Qin; Tobias Kurth; Christian Waeber; Michel D Ferrari; Arn M J M van den Maagdenberg; Michael A Moskowitz; Cenk Ayata Journal: Circulation Date: 2011-12-05 Impact factor: 29.690
Authors: Ying Wei; Muge Yemisci; Hyung-Hwan Kim; Lai Ming Yung; Hwa Kyoung Shin; Seo-Kyoung Hwang; Shuzhen Guo; Tao Qin; Nafiseh Alsharif; Volker Brinkmann; James K Liao; Eng H Lo; Christian Waeber Journal: Ann Neurol Date: 2010-11-12 Impact factor: 10.422
Authors: T A Tomsick; P Khatri; T Jovin; B Demaerschalk; T Malisch; A Demchuk; M D Hill; E Jauch; J Spilker; J P Broderick Journal: Neurology Date: 2010-03-30 Impact factor: 9.910
Authors: Dimitrios Papadopoulos; Jon Rundle; Ryan Patel; Ian Marshall; Jennifer Stretton; Rachel Eaton; Jill C Richardson; Maria I Gonzalez; Karen L Philpott; Richard Reynolds Journal: J Neurosci Res Date: 2010-02-01 Impact factor: 4.164
Authors: Waltraud Pfeilschifter; Bożena Czech-Zechmeister; Marian Sujak; Ana Mirceska; Alexander Koch; Abdelhaq Rami; Helmuth Steinmetz; Christian Foerch; Andrea Huwiler; Josef Pfeilschifter Journal: Biochem Biophys Res Commun Date: 2011-08-22 Impact factor: 3.575
Authors: Werner Hacke; Markku Kaste; Erich Bluhmki; Miroslav Brozman; Antoni Dávalos; Donata Guidetti; Vincent Larrue; Kennedy R Lees; Zakaria Medeghri; Thomas Machnig; Dietmar Schneider; Rüdiger von Kummer; Nils Wahlgren; Danilo Toni Journal: N Engl J Med Date: 2008-09-25 Impact factor: 91.245
Authors: Cyrille Orset; Richard Macrez; Alan R Young; Didier Panthou; Eduardo Angles-Cano; Eric Maubert; Veronique Agin; Denis Vivien Journal: Stroke Date: 2007-08-16 Impact factor: 7.914
Authors: Bozena Czech; Waltraud Pfeilschifter; Niloufar Mazaheri-Omrani; Marc André Strobel; Timo Kahles; Tobias Neumann-Haefelin; Abdelhaq Rami; Andrea Huwiler; Josef Pfeilschifter Journal: Biochem Biophys Res Commun Date: 2009-08-29 Impact factor: 3.575
Authors: Michael J Van Kanegan; Dong Ning He; Denise E Dunn; Peiying Yang; Robert A Newman; Anne E West; Donald C Lo Journal: J Neurosci Date: 2014-01-15 Impact factor: 6.167
Authors: Emmanuel Touzé; Denis Vivien; Cyrille Orset; Benoit Haelewyn; Stuart M Allan; Saema Ansar; Francesco Campos; Tae Hee Cho; Anne Durand; Mohamad El Amki; Marc Fatar; Isaac Garcia-Yébenes; Maxime Gauberti; Saskia Grudzenski; Ignacio Lizasoain; Eng Lo; Richard Macrez; Isabelle Margaill; Samaneh Maysami; Stephen Meairs; Norbert Nighoghossian; Josune Orbe; Jose Antonio Paramo; Jean-Jacques Parienti; Nancy J Rothwell; Marina Rubio; Christian Waeber; Alan R Young Journal: Stroke Date: 2016-03-31 Impact factor: 7.914